TUCSON, Ariz., November 19, 2024 — Critical Path Institute® (C-Path) today announced that its Translational Therapeutics Accelerator (TRxA) program, in partnership with The Leona M. and Harry B.
TUCSON, Ariz., June 18, 2025 — Critical Path Institute’s® (C-Path) Translational Therapeutics Accelerator (TRxA) proudly announced today a $250,000 grant award aimed at developing a novel treatment ...
The Tucson-based Critical Path Institute was founded in 2005 as a public-private partnership with the U.S. Food and Drug Administration. Its main goal is to improve the drug-development process so ...
Critical Path Institute’s Translational Therapeutics Accelerator has invested in the development of QED-203 for advanced and therapy-resistant prostate cancer. Based on research at the University of ...